Eli Lilly climbed on win for rival weight-loss drug, and we still feel good about Abbott Labs

The Investing Club releases the Homestretch, an actionable afternoon update just in time for the last hour of trading. We still feel good about Abbott Labs, but don't think it's too late for the company's stock market. We're happy with the news, but we're not happy with Abbott Labs.

Investing Club releases the Homestretch, an actionable afternoon update just in time for the last hour of trading. Here is Eli Lilly's competitive edge in GLP-1 obesity drugs and Abbott's secondary play. Abbott's second-tier play in the obesity drug market.

Investing Club releases the Homestretch, an actionable afternoon update just in time for the last hour of trading. Here is Eli Lilly's competitive edge in GLP-1 obesity drugs and Abbott's secondary play. Abbott's second-tier play in the obesity drug market.

Eli Lilly is trying to remind patients how to use weight-loss-related drugs appropriately. The company has a new campaign to educate patients on how to properly use the drugs. Eli Lilly: "Weight-loss drugs have proliferated in recent years, and we need to be careful with them"